

## Contents

### Part I Directed Evolution 1

<b>1</b>	<b>Continuous Evolution of Proteins <i>In Vivo</i></b>	<b>3</b>
	<i>Alon Wellner, Arjun Ravikumar, and Chang C. Liu</i>	
1.1	Introduction	3
1.2	Challenges in Achieving <i>In Vivo</i> Continuous Evolution	5
1.3	Phage-Assisted Continuous Evolution (PACE)	10
1.4	Systems That Allow <i>In Vivo</i> Continuous Directed Evolution	13
1.4.1	Targeted Mutagenesis in <i>E. coli</i> with Error-Prone DNA Polymerase I	13
1.4.2	Yeast Systems That Do Not Use Engineered DNA Polymerases for Mutagenesis	16
1.4.3	Somatic Hypermutation as a Means for Targeted Mutagenesis of GOIs	18
1.4.4	Orthogonal DNA Replication (OrthoRep)	20
1.5	Conclusion	22
	References	22
<b>2</b>	<b><i>In Vivo</i> Biosensors for Directed Protein Evolution</b>	<b>29</b>
	<i>Song Buck Tay and Ee Lui Ang</i>	
2.1	Introduction	29
2.2	Nucleic Acid-Based <i>In Vivo</i> Biosensors for Directed Protein Evolution	32
2.2.1	RNA-Type Biosensors	32
2.2.2	DNA-Type Biosensors	35
2.3	Protein-Based <i>In Vivo</i> Biosensors for Directed Protein Evolution	37
2.3.1	Transcription Factor-Type Biosensors	37
2.3.2	Enzyme-Type Biosensors	41
2.4	Characteristics of Biosensors for <i>In Vivo</i> Directed Protein Evolution	44
2.5	Conclusions and Future Perspectives	45
	Acknowledgments	46
	References	46

<b>3</b>	<b>High-Throughput Mass Spectrometry Complements Protein Engineering</b>	<b>57</b>
	<i>Tong Si, Pu Xue, Kisurb Choe, Huimin Zhao, and Jonathan V. Sweedler</i>	
3.1	Introduction	57
3.2	Procedures and Instrumentation for MS-Based Protein Assays	59
3.3	Technology Advances Focusing on Throughput Improvement	62
3.4	Applications of MS-Based Protein Assays: Summary	63
3.4.1	Applications of MS-Based Assays: Protein Analysis	64
3.4.2	Applications of MS-Based Assays: Protein Engineering	66
3.5	Conclusions and Perspectives	68
	Acknowledgments	68
	References	69
<b>4</b>	<b>Recent Advances in Cell Surface Display Technologies for Directed Protein Evolution</b>	<b>81</b>
	<i>Maryam Raeeszadeh-Sarmazdeh and Wilfred Chen</i>	
4.1	Cell Display Methods	81
4.1.1	Phage Display	81
4.1.2	Bacterial Display Systems	83
4.1.3	Yeast Surface Display	84
4.1.4	Mammalian Display	85
4.2	Selection Methods and Strategies	86
4.2.1	High-Throughput Cell Screening	86
4.2.1.1	Panning	86
4.2.1.2	FACS	86
4.2.1.3	MACS	87
4.2.2	Selection Strategies	88
4.2.2.1	Competitive Selection (Counter Selection)	88
4.2.2.2	Negative/Positive Selection	89
4.3	Modifications of Cell Surface Display Systems	89
4.3.1	Modification of YSD for Enzyme Engineering	89
4.3.2	Yeast Co-display System	91
4.3.3	Surface Display of Multiple Proteins	91
4.4	Recent Advances to Expand Cell-Display Directed Evolution Techniques	93
4.4.1	$\mu$ SCALE (Microcapillary Single-Cell Analysis and Laser Extraction)	93
4.4.2	Combining Cell Surface Display and Next-Generation Sequencing	94
4.4.3	PACE (Phage-Assisted Continuous Evolution)	94
4.5	Conclusion and Outlook	96
	References	97
<b>5</b>	<b>Iterative Saturation Mutagenesis for Semi-rational Enzyme Design</b>	<b>105</b>
	<i>Ge Qu, Zhoutong Sun, and Manfred T. Reetz</i>	
5.1	Introduction	105
5.2	Recent Methodology Developments in ISM-Based Directed Evolution	108

5.2.1	Choosing Reduced Amino Acid Alphabets Properly	109
5.2.1.1	Limonene Epoxide Hydrolase as the Catalyst in Hydrolytic Desymmetrization	109
5.2.1.2	Alcohol Dehydrogenase TbSADH as the Catalyst in Asymmetric Transformation of Difficult-to-Reduce Ketones	110
5.2.1.3	P450-BM3 as the Chemo- and Stereoselective Catalyst in a Whole-Cell Cascade Sequence	112
5.2.1.4	Multi-parameter Evolution Aided by Mutability Landscaping	115
5.2.2	Further Methodology Developments of CAST/ISM	117
5.2.2.1	Advances Based on Novel Molecular Biological Techniques and Computational Methods	117
5.2.2.2	Advances Based on Solid-Phase Chemical Synthesis of SM Libraries	118
5.3	B-FIT as an ISM Method for Enhancing Protein Thermostability	120
5.4	Learning from CAST/ISM-Based Directed Evolution	121
5.5	Conclusions and Perspectives	121
	Acknowledgment	124
	References	124

## Part II Rational and Semi-Rational Design 133

<b>6</b>	<b>Data-driven Protein Engineering</b>	<b>135</b>
	<i>Jonathan Greenhalgh, Apoorv Saraogee, and Philip A. Romero</i>	
6.1	Introduction	135
6.2	The Data Revolution in Biology	136
6.3	Statistical Representations of Protein Sequence, Structure, and Function	138
6.3.1	Representing Protein Sequences	138
6.3.2	Representing Protein Structures	140
6.4	Learning the Sequence-Function Mapping from Data	141
6.4.1	Supervised Learning (Regression/Classification)	141
6.4.2	Unsupervised/Semisupervised Learning	144
6.5	Applying Statistical Models to Engineer Proteins	145
6.6	Conclusions and Future Outlook	147
	References	148
<b>7</b>	<b>Protein Engineering by Efficient Sequence Space Exploration Through Combination of Directed Evolution and Computational Design Methodologies</b>	<b>153</b>
	<i>Subrata Pramanik, Francisca Contreras, Mehdi D. Davari, and Ulrich Schwaneberg</i>	
7.1	Introduction	153
7.2	Protein Engineering Strategies	154
7.2.1	Computer-Aided Rational Design	155
7.2.1.1	FRESCO	155
7.2.1.2	FoldX	157

7.2.1.3	CNA	158
7.2.1.4	PROSS	159
7.2.1.5	ProSAR	160
7.2.2	Knowledge Based Directed Evolution	161
7.2.2.1	Iterative Saturation Mutagenesis (ISM)	161
7.2.2.2	Mutagenic Organized Recombination Process by Homologous <i>In Vivo</i> Grouping (MORPHING)	161
7.2.2.3	Knowledge Gaining Directed Evolution (KnowVolution)	162
7.3	Conclusions and Future Perspectives	171
	Acknowledgments	171
	References	171
<b>8</b>	<b>Engineering Artificial Metalloenzymes</b>	<b>177</b>
	<i>Kevin A. Harnden, Yajie Wang, Lam Vo, Huimin Zhao, and Yi Lu</i>	
8.1	Introduction	177
8.2	Rational Design	177
8.2.1	Rational Design of Metalloenzymes Using <i>De Novo</i> Designed Scaffolds	177
8.2.2	Rational Design of Metalloenzymes Using Native Scaffolds	179
8.2.2.1	Redesign of Native Proteins	179
8.2.2.2	Cofactor Replacement in Native Proteins	181
8.2.2.3	Covalent Anchoring in Native Protein	184
8.2.2.4	Supramolecular Anchoring in Native Protein	187
8.3	Engineering Artificial Metalloenzyme by Directed Evolution in Combination with Rational Design	188
8.3.1	Directed Evolution of Metalloenzymes Using <i>De Novo</i> Designed Scaffolds	188
8.3.2	Directed Evolution of Metalloenzymes Using Native Scaffolds	189
8.3.2.1	Cofactor Replacement in Native Proteins	189
8.3.2.2	Covalent Anchoring in Native Protein	192
8.3.2.3	Non-covalent Anchoring in Native Proteins	194
8.4	Summary and Outlook	200
	Acknowledgment	201
	References	201
<b>9</b>	<b>Engineered Cytochromes P450 for Biocatalysis</b>	<b>207</b>
	<i>Hanan Alwaseem and Rudi Fasan</i>	
9.1	Cytochrome P450 Monooxygenases	207
9.2	Engineered Bacterial P450s for Biocatalytic Applications	210
9.2.1	Oxyfunctionalization of Small Organic Substrates	211
9.2.2	Late-Stage Functionalization of Natural Products	220
9.2.3	Synthesis of Drug Metabolites	224
9.3	High-throughput Methods for Screening Engineered P450s	227
9.4	Engineering of Hybrid P450 Systems	229
9.5	Engineered P450s with Improved Thermostability and Solubility	230

9.6	Conclusions	231
	Acknowledgments	232
	References	232

### Part III Applications in Industrial Biotechnology 243

<b>10</b>	<b>Protein Engineering Using Unnatural Amino Acids</b>	<b>245</b>
	<i>Yang Yu, Xiaohong Liu, and Jiangyun Wang</i>	
10.1	Introduction	245
10.2	Methods for Unnatural Amino Acid Incorporation	246
10.3	Applications of Unnatural Amino Acids in Protein Engineering	247
10.3.1	Enhancing Stability	248
10.3.2	Mechanistic Study Using Spectroscopic Methods	248
10.3.3	Tuning Catalytic Activity	250
10.3.4	Tuning Selectivity	252
10.3.5	Enzyme Design	252
10.3.6	Protein Engineering Toward a Synthetic Life	255
10.4	Outlook	256
10.5	Conclusions	258
	References	258
<b>11</b>	<b>Application of Engineered Biocatalysts for the Synthesis of Active Pharmaceutical Ingredients (APIs)</b>	<b>265</b>
	<i>Juan Mangas-Sanchez, Sebastian C. Cosgrove, and Nicholas J. Turner</i>	
11.1	Introduction	265
11.1.1	Transferases	266
11.1.1.1	Transaminases	266
11.1.2	Oxidoreductases	267
11.1.2.1	Ketoreductases	267
11.1.2.2	Amino Acid Dehydrogenases	271
11.1.2.3	Cytochrome P450 Monooxygenases	272
11.1.2.4	Baeyer–Villiger Monooxygenases	273
11.1.2.5	Amine Oxidases	274
11.1.2.6	Hydroxylases	276
11.1.2.7	Imine Reductases	276
11.1.3	Lyases	278
11.1.3.1	Ammonia Lyases	278
11.1.4	Isomerases	278
11.1.5	Hydrolases	279
11.1.5.1	Esterases	279
11.1.5.2	Haloalkane Dehalogenase	279
11.1.6	Multi-enzyme Cascade	281
11.2	Conclusions	282
	References	287

<b>12</b>	<b>Directing Evolution of the Fungal Ligninolytic Secretome</b>	<b>295</b>
	<i>Javier Viña-Gonzalez and Miguel Alcalde</i>	
12.1	The Fungal Ligninolytic Secretome	295
12.2	Functional Expression in Yeast	297
12.2.1	The Evolution of Signal Peptides	297
12.2.2	Secretion Mutations in Mature Protein	300
12.2.3	The Importance of Codon Usage	301
12.3	Yeast as a Tool-Box in the Generation of DNA Diversity	302
12.4	Bringing Together Evolutionary Strategies and Computational Tools	305
12.5	High-Throughput Screening (HTS) Assays for Ligninase Evolution	306
12.6	Conclusions and Outlook	309
	Acknowledgments	309
	References	310
<b>13</b>	<b>Engineering Antibody-Based Therapeutics: Progress and Opportunities</b>	<b>317</b>
	<i>Annalee W. Nguyen and Jennifer A. Maynard</i>	
13.1	Introduction	317
13.2	Antibody Formats	318
13.2.1	Human IgG1 Structure	318
13.2.2	Antibody-Drug Conjugates	319
13.2.3	Bispecific Antibodies	320
13.2.4	Single Domain Antibodies	321
13.2.5	Chimeric Antigen Receptors	321
13.3	Antibody Discovery	322
13.3.1	Antibody Target Identification	322
13.3.1.1	Cancer and Autoimmune Disease Targets	323
13.3.1.2	Infectious Disease Targets	323
13.3.2	Screening for Target-Binding Antibodies	324
13.3.2.1	Synthetic Library Derived Antibodies	324
13.3.2.2	Host-Derived Antibodies	325
13.3.2.3	Immunization	325
13.3.2.4	Pairing the Light and Heavy Variable Regions	326
13.3.2.5	Humanization	327
13.3.2.6	Hybrid Approaches to Antibody Discovery	328
13.4	Therapeutic Optimization of Antibodies	328
13.4.1	Serum Half-Life	328
13.4.1.1	Antibody Half-Life Extension	329
13.4.1.2	Antibody Half-Life Reduction	331
13.4.1.3	Effect of Half-Life Modification on Effector Functions	331

13.4.2	Effector Functions	331
13.4.2.1	Effector Function Considerations for Cancer Therapeutics	332
13.4.2.2	Effector Function Considerations for Infectious Disease Prophylaxis and Therapy	333
13.4.2.3	Effector Function Considerations for Treating Autoimmune Disease	334
13.4.2.4	Approaches to Engineering the Effector Functions of the IgG1 Fc	334
13.4.3	Tissue Localization	335
13.4.4	Immunogenicity	335
13.4.4.1	Reducing T-Cell Recognition	336
13.4.4.2	Reducing Aggregation	336
13.5	Manufacturability of Antibodies	336
13.5.1	Increasing Antibody Yield	337
13.5.1.1	Codon Usage	337
13.5.1.2	Signal Peptide Optimization	337
13.5.1.3	Expression Optimization	338
13.5.2	Alternative Production Methods	338
13.6	Conclusions	339
	Acknowledgments	339
	References	339

## **14 Programming Novel Cancer Therapeutics: Design Principles for Chimeric Antigen Receptors 353**

*Andrew J. Hou and Yvonne Y. Chen*

14.1	Introduction	353
14.2	Metrics to Evaluate CAR-T Cell Function	354
14.3	Antigen-Recognition Domain	356
14.3.1	Tuning the Antigen-Recognition Domain to Manage Toxicity	356
14.3.2	Incorporation of Multiple Antigen-Recognition Domains to Engineer “Smarter” CARs	356
14.3.3	Novel Antigen-Recognition Domains to Enhance CAR Modularity	359
14.3.4	Engineering CARs that Target Soluble Factors	360
14.4	Extracellular Spacer	360
14.5	Transmembrane Domain	362
14.6	Signaling Domain	362
14.6.1	First- and Second-Generation CARs	362
14.6.2	Combinatorial Co-stimulation	363
14.6.3	Other Co-stimulatory Domains: ICOS, OX40, TLR2	364
14.6.4	Additional Considerations for CAR Signaling Domains	364
14.7	High-Throughput CAR Engineering	366
14.8	Novel Receptor Modalities	367
	References	369

## Part IV Applications in Medical Biotechnology 377

<b>15</b>	<b>Development of Novel Cellular Imaging Tools Using Protein Engineering 379</b>
	<i>Praopim Limsakul, Chi-Wei Man, Qin Peng, Shaoying Lu, and Yingxiao Wang</i>
15.1	Introduction 379
15.2	Cellular Imaging Tools Developed by Protein Engineering 380
15.2.1	Fluorescent Proteins 380
15.2.1.1	The FP Color Palette 380
15.2.1.2	Photocontrollable Fluorescent Proteins 381
15.2.1.3	Other Engineered Fluorescent Proteins 383
15.2.2	Antibodies and Protein Scaffolds 383
15.2.2.1	Antibodies 383
15.2.2.2	Antibody-Like Protein Scaffolds 384
15.2.2.3	Directed Evolution 384
15.2.3	Genetically Encoded Non-fluorescent Protein Tags 385
15.3	Application in Cellular Imaging 386
15.3.1	Cell Biology Applications 386
15.3.1.1	Localization 386
15.3.1.2	Cell Signaling 387
15.3.2	Application in Diagnostics and Medicine 390
15.3.2.1	Detection 390
15.3.2.2	Screening for Drugs 392
15.4	Conclusion and Perspectives 393
	References 394
	<b>Index 403</b>